Monoclonal antibody imaging in the management of recurrent ovarian cancer

R. A. Lawhead, Hadyn T Williams

Research output: Contribution to journalArticle

Abstract

More than 65% of women with ovarian cancer will experience recurrences. Second-line chemotherapeutic agents show promise in treating these recurrences, but there is no ideal method of early detection. By localizing residual or recurrent tumors not detected by standard radiographic modalities (eg, computed tomography), monoclonal antibody imaging may facilitate a more informed, cost-effective assessment of the relative risks and benefits of additional surgery, chemotherapy, or no further treatment in patients at risk.

Original languageEnglish (US)
Pages (from-to)67-72,74
JournalFemale Patient - OB/GYN Edition
Volume20
Issue number12
StatePublished - Dec 1 1995

Fingerprint

Ovarian Neoplasms
Monoclonal Antibodies
Recurrence
Tomography
Costs and Cost Analysis
Drug Therapy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Monoclonal antibody imaging in the management of recurrent ovarian cancer. / Lawhead, R. A.; Williams, Hadyn T.

In: Female Patient - OB/GYN Edition, Vol. 20, No. 12, 01.12.1995, p. 67-72,74.

Research output: Contribution to journalArticle

@article{0dea983e479b4c528d15736bebb71dfd,
title = "Monoclonal antibody imaging in the management of recurrent ovarian cancer",
abstract = "More than 65{\%} of women with ovarian cancer will experience recurrences. Second-line chemotherapeutic agents show promise in treating these recurrences, but there is no ideal method of early detection. By localizing residual or recurrent tumors not detected by standard radiographic modalities (eg, computed tomography), monoclonal antibody imaging may facilitate a more informed, cost-effective assessment of the relative risks and benefits of additional surgery, chemotherapy, or no further treatment in patients at risk.",
author = "Lawhead, {R. A.} and Williams, {Hadyn T}",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "20",
pages = "67--72,74",
journal = "Female Patient - OB/GYN Edition",
issn = "0888-2401",
publisher = "Quadrant Healthcom Inc.",
number = "12",

}

TY - JOUR

T1 - Monoclonal antibody imaging in the management of recurrent ovarian cancer

AU - Lawhead, R. A.

AU - Williams, Hadyn T

PY - 1995/12/1

Y1 - 1995/12/1

N2 - More than 65% of women with ovarian cancer will experience recurrences. Second-line chemotherapeutic agents show promise in treating these recurrences, but there is no ideal method of early detection. By localizing residual or recurrent tumors not detected by standard radiographic modalities (eg, computed tomography), monoclonal antibody imaging may facilitate a more informed, cost-effective assessment of the relative risks and benefits of additional surgery, chemotherapy, or no further treatment in patients at risk.

AB - More than 65% of women with ovarian cancer will experience recurrences. Second-line chemotherapeutic agents show promise in treating these recurrences, but there is no ideal method of early detection. By localizing residual or recurrent tumors not detected by standard radiographic modalities (eg, computed tomography), monoclonal antibody imaging may facilitate a more informed, cost-effective assessment of the relative risks and benefits of additional surgery, chemotherapy, or no further treatment in patients at risk.

UR - http://www.scopus.com/inward/record.url?scp=0029560658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029560658&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029560658

VL - 20

SP - 67-72,74

JO - Female Patient - OB/GYN Edition

JF - Female Patient - OB/GYN Edition

SN - 0888-2401

IS - 12

ER -